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Objectives This study examined short-term cardiac catheterization rates and medication changes after cardiac imaging.
Background Noninvasive cardiac imaging is widely used in coronary artery disease, but its effects on subsequent patient
management are unclear.
Methods We assessed the 90-day post-test rates of catheterization and medication changes in a prospective registry of
1,703 patients without a documented history of coronary artery disease and an intermediate to high likelihood
of coronary artery disease undergoing cardiac single-photon emission computed tomography, positron emission
tomography, or 64-slice coronary computed tomography angiography.
Results Baseline medication use was relatively infrequent. At 90 days, 9.6% of patients underwent catheterization. The
rates of catheterization and medication changes increased in proportion to test abnormality findings. Among
patients with the most severe test result findings, 38% to 61% were not referred to catheterization, 20% to 30%
were not receiving aspirin, 35% to 44% were not receiving a beta-blocker, and 20% to 25% were not receiving a
lipid-lowering agent at 90 days after the index test. Risk-adjusted analyses revealed that compared with stress
single-photon emission computed tomography or positron emission tomography, changes in aspirin and lipid-
lowering agent use was greater after computed tomography angiography, as was the 90-day catheterization re-
ferral rate in the setting of normal/nonobstructive and mildly abnormal test results.
Conclusions Overall, noninvasive testing had only a modest impact on clinical management of patients referred for clinical
testing. Although post-imaging use of cardiac catheterization and medical therapy increased in proportion to the
degree of abnormality findings, the frequency of catheterization and medication change suggests possible un-
dertreatment of higher risk patients. Patients were more likely to undergo cardiac catheterization after com-
puted tomography angiography than after single-photon emission computed tomography or positron emission
tomography after normal/nonobstructive and mildly abnormal study findings. (Study of Perfusion and Anatomy’s
Role in Coronary Artery [CAD] [SPARC]; NCT00321399) (J Am Coll Cardiol 2012;59:462–74) © 2012 by the
American College of Cardiology Foundation
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January 31, 2012:462–74 Patient Management After Cardiac ImagingThe use of noninvasive cardiac imaging is recommended in
numerous clinical scenarios by current guidelines and appro-
priate use documents as a diagnostic and prognostic tool to
improve efficiency of further testing and enhance risk stratifi-
cation for coronary artery disease (CAD), especially in patients
with an intermediate likelihood of CAD (1–3). Nonetheless,
critics have pointed out that despite the widespread use of
noninvasive cardiac imaging, there is no clinical trial evidence
that this practice results in improved health outcomes or a
decrease in long-term medical costs (4). There is also concern
about the potential risks associated with radiation exposure
from medical imaging. On the other hand, advocates claim
that incorporating imaging into a testing strategy results in
superior diagnostic accuracy, improved cost-effectiveness of
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hanced patient benefit (5,6). Al-
though these claims have been
widely made, evidence is sparse
that the use of these expensive
modalities actually alters post-
imaging patient management.
The goal of the current study
was to examine post-imaging,
short-term patient management
as measured by referral to cathe-
terization and changes in medical
therapy at 90 days after the index
study in patients without previ-
ous CAD referred for elective
noninvasive cardiovascular imaging and recruited to the
SPARC (Study of Myocardial Perfusion and Coronary
Anatomy Imaging Roles in CAD).
Methods
Study design. The details of the SPARC design and
methods of analyses were previously published (7). The
current analysis is limited to patients without previous CAD
with an intermediate to high CAD likelihood enrolled in
the SPARC. Clinically stable patients presenting for elec-
tive, clinically indicated cardiac imaging (myocardial perfu-
sion imaging [MPI], single-photon emission computed
tomography [SPECT] or positron emission tomography
[PET], and coronary computed tomography angiography
[CTA]) were enrolled. Participating sites included hospitals
and outpatient offices, academic and nonacademic sites, and
community and tertiary care centers. A total of 1,717
consecutive patients without previous CAD were enrolled in
the SPARC. At 90 days after the index study, 5 patients
(0.3%) were lost to follow-up and 9 patients (0.5%) with-
drew consent, leaving 1,703 patients with 90-day follow-up
for analysis. No patients had missing data for any variable.
This study was approved by the institutional review com-
mittee at each study site, and all enrolled patients provided
both written informed consent and HIPAA (Health Insurance
Portability and Accountability Act) release before index study
procedures for study endpoint records collection.
Performance, interpretation, and scoring of the index
imaging study. All studies, image acquisition, and image
processing followed each site’s institutional protocol. As
patient management decisions were based on the clinically
reported interpretations, analyses of patient management
were based on the reported site interpretation rather than a
core laboratory interpretation of imaging results.
MYOCARDIAL PERFUSION IMAGES. SPECT and PET find-
ngs were assessed using semiquantitative visual assessment
f regional myocardial perfusion using the recommended
7-segment/4-point scoring system, as previously described
7). Segmental scoring was performed by site readers fol-
Abbreviations
and Acronyms
CAD  coronary artery
disease
CCTA  coronary
computed tomography
angiography
MPI  myocardial perfusion
imaging
PET  positron emission
tomography
SPECT  single-photon
emission computed
tomographyowing study guidelines (7).
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scores and converted to a percentage of myocardium fixed,
abnormal, or ischemic (the percentage of total myocardium
involved with stress, ischemic, or fixed defects), by dividing
the summed scores by 51 and multiplying by 100, as
previously described (7).
CCTA IMAGES. CTA study findings were interpreted and
cored using the American College of Cardiology/American
eart Association–recommended segmentation schema, as
reviously described (7). For each coronary segment, segment
ccessibility, plaque presence, stenosis severity, plaque compo-
ition (calcified, predominantly noncalcified, or complex), and
tent presence were recorded.
DERIVED INDICES. The pre-test likelihood of CAD as a
continuous variable was calculated using the method of Pryor
et al. (8). Hospital status was defined on the basis of whether
the imaging center was located in a hospital and academic
status on the basis of the site principal investigator’s self-
reporting. Dyspnea and type of chest pain were considered as
separate variables.
To permit direct comparison of myocardial perfusion imag-
ing (MPI) and CCTA data, a 3-category variable was pre-
defined as follows: 1) normal/nonobstructive included CCTA
with either normal coronary arteries or with nonobstructive
CAD, and normal myocardial perfusion by SPECT or PET;
2) mildly abnormal included CCTA showing evidence of
obstructive CAD (at least 1 epicardial coronary artery with
70%) but without high-risk anatomic features (i.e., left main
stenosis 50%, 70% stenosis in the proximal left anterior
escending artery, or 3-vessel CAD with 70% stenosis) (9),
nd a myocardial perfusion SPECT or PET study demonstrat-
ng mild abnormality (0% but 10% myocardium abnor-
al); 3) moderate to severe abnormality included CCTA
howing evidence of high-risk anatomic features as defined
reviously, and a myocardial perfusion SPECT or PET study
howing a moderate to severe abnormality (10% myocar-
ium abnormal). For purposes of dichotomization, categories 2
nd 3 were included in the abnormal category and 1 in the
ormal category.
tudy endpoints. The primary endpoints of this study are:
) referral for catheterization within 90 days of the index study;
nd 2) change in cardiac medication use between baseline and
0 days (medication dose change [increase or decrease], dis-
ontinuation, or addition of a new medication). We limited
ur analysis to the use of aspirin, beta-blockers, and lipid-
owering agents. Referral to revascularization within 90 days
fter noninvasive procedures was a secondary endpoint. Infor-
ation regarding invasive procedures and medication use were
btained directly from patient interview. The occurrence of
atheterization and revascularization and the results of cathe-
erization were ascertained from operative and procedural
eports.
ardiac catheterization results. CAD presence and extent
ere determined from catheterization reports by 2 indepen-
ent readers, with discrepancies adjudicated by consensus. mbstructive CAD was defined as stenosis of 50% of the left
ain coronary artery or 70% of a major epicardial or branch
essel. Patients with definite atherosclerosis but with coronary
tenosis of 50% of the left main coronary artery or 70% of
major epicardial or branch vessel were considered to have
onobstructive CAD. Patients without evidence of angio-
raphic atherosclerosis were categorized as having normal
oronary arteries.
tatistical analysis. Continuous variables are presented as
ean  1 SD and categorical variables as percentages. Con-
inuous variables were compared with a t test (pairwise com-
arisons) or analysis of variance (multigroup comparisons) and
ategorical variables with a chi-square test. A Bonferroni
djustment was applied as appropriate for multiple compari-
ons. Analysis of medication change as a function of study
esults and imaging modality was performed for aspirin,
ipid-lowering agents, and beta-blockers. A Cochran-Mantel-
aenszel chi-square test was used to examine the association of
ime (baseline vs. 90 days) and study results with respect to
requency of medication use. Post-hoc comparisons across
odalities were performed at each level of study result using a
hi-square test of association with significance determined by a
onferroni adjustment using 3 comparisons.
For each outcome, a generalized linear mixed model, a
ierarchical model, was applied by including regions and sites
s random effects to account for the possible variability of the
egions and sites within each region. A logistic link was used
or the binary outcome. All interesting covariates were consid-
red as fixed effects, whereas regions and sites within each
egion as random effects. This analysis was done by the
unction of “glmer” in R library lme4 (The Comprehensive R
rchive Network, The R Foundation for Statistical Comput-
ng). Contrasts were used to compare across modalities at each
tudy result with significance determined by a Bonferroni
orrected p value with 3 comparisons.
esults
atient characteristics. Table 1 summarizes the baseline
haracteristics of patients in the study. The 1,703-patient
ohort was evenly divided among the 3 imaging modalities.
isk factors were prevalent. More than three fourths of
atients presented with angina; 30% of patients reported
yspnea. Aspirin, beta-blockers, and lipid-lowering agents
ere the most commonly used medications at baseline.
As part of the SPARC, sites collected data on 7,872
atients presenting for testing but not enrolling in the
PARC. Due to institutional review board constraints, the
ata collected on these patients were limited to age, race,
nd sex. Compared with the patients in the current study,
atients in the SPARC screening registry were slightly older
age 63 14 years), more frequently white (86%), and more
requently male (54%).
Overall, 26% of patients had abnormal noninvasive im-
ging results. Of these, 18% were mildly abnormal and 8%
oderately to severely abnormal. Normal or nonobstructive
rtery di
puted t
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January 31, 2012:462–74 Patient Management After Cardiac Imagingimaging results were present in 82% undergoing CCTA,
62% undergoing PET, and 78% undergoing SPECT studies
(p 0.001). In the SPECT arm, 65% (n 368) of patients
underwent exercise stress, 28% (n  158) underwent phar-
macologic stress only, and an additional 7% (n  40)
underwent combined pharmacologic stress with adjunct
exercise stress. All patients in the PET arm underwent
pharmacologic stress.
Overall, 17% of patients in the study had stress and/or
other imaging tests within 90 days before their index
imaging study (Fig. 1). The frequency of previous testing
among patients undergoing CCTA as their index study was
twice as high as that of those undergoing PET and 6 times
higher than those undergoing SPECT.
Referral for cardiac catheterization after noninvasive
imaging tests. Catheterization was performed in 9.6% of
patients (n 163), in 35 patients (2.8%) with normal/
nonobstructive results, in 61 patients (20.3%) with mildly
Baseline Characteristics for Study PopulationTable 1 Baseline Characteristics for Study P
SPECT
(n  565)
Demographics
Age, yrs 60 11
Male 49% (279)
White race 68% (386)
Body mass index, kg/m2 30 7
Baseline medical history
Diabetes 31% (173)
Smoking, within 5 yrs 20% (110)
High/elevated cholesterol 60% (338)
Hypertension 66% (371)
Family history of
premature CAD
29% (165)
Atrial fibrillation 5% (30)
Baseline medications
Aspirin 41% (230)
Lipid-lowering drugs 44% (250)
Beta-blockers 30% (172)
ACE inhibitors 28% (158)
Angiotensin receptor
blocker
9% (51)
Diuretics 23% (129)
Calcium channel blockers 16% (92)
Nitrates 5% (30)
Clopidogrel 2% (9)
Antiarrhythmic agents 1% (7)
Presenting cardiac
symptoms
Asymptomatic 11% (63)
Anginal symptoms 79% (449)
Noncardiac chest pain 4% (21)
Dyspnea 24% (136)
Likelihood of CAD 0.38 0.29
Values are mean  SD or % (n). *p  0.05 versus SPECT based on t
ACE  angiotensin-converting enzyme inhibitor; CAD  coronary a
positron emission tomography; SPECT  single-photon emission comabnormal, and in 67 patients (48.2%) with moderately toseverely abnormal study results (p  0.001). Referral to
catheterization within 90 days occurred in 24 patients (4.3%)
after SPECT, in 61 patients (11.1%) after PET, and in 78
patients (13.2%) after CCTA (p  0.001). The frequency of
catheterization was greater after CCTA than after SPECT or
PET across the entire spectrum of study results, although it
was only statistically different in the setting of normal/
nonobstructive or mildly abnormal study results (Fig. 2A).
However, when normal CCTA findings were defined as the
absence of any abnormality on CCTA, the referral for cathe-
terization rate after normal CCTA results decreased from 5.2%
to 1.7%, and the intermodality difference was no longer
present. There were no significant changes in these results
when the frequencies of catheterization were considered as a
function of stress defects rather than ischemic defects.
MULTIVARIABLEMODELINGOFCATHETERIZATIONREFERRAL.
Multivariable modeling using recruitment site and the site’s
ation
x Modality
Total Patients
(N  1,703)
PET
 548)
CCTA
(n  590)
 11* 58 11.4 62 11
% (225)* 52% (308) 48% (812)
% (439)* 87% (513) 82% (1,396)
 10* 29 6 31 7
% (225)* 16% (94)* 29% (492)
% (64)* 16% (97)* 16% (271)
% (356)* 63% (370)* 62% (1,064)
% (398)* 56% (328)* 64% (1,097)
% (130)* 37% (220)* 30% (515)
% (44) 5% (30) 6% (104)
% (256) 47% (278) 45% (764)
% (288) 50% (295) 49% (833)
% (211) 29% (170) 32% (553)
% (193) 20% (116) 27% (467)
% (71) 10% (60) 11% (182)
% (189) 18% (105) 25% (423)
% (99) 11% (66) 15% (257)
% (24) 5% (31) 5% (85)
% (18) 3% (19) 3% (46)
% (12) 2% (13) 2% (32)
% (63) 10% (60) 11% (186)
% (370)* 85% (504)* 78% (1,323)
% (29) 2% (13) 4% (63)
% (239)* 23% (134) 30% (509)
 0.33 0.41 0.39 0.41 0.33
ng a Bonferroni adjustment of 0.025 for 2 comparisons.
sease; CCTA  coronary computed tomography angiography; PET 
omography.opul
Inde
(n
63
41
80
34
41
12
65
73
24
8
47
53
39
35
13
35
18
4
3
2
11
68
5
44
0.45
test usigeographic location as random effects revealed that after
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Patient Management After Cardiac Imaging January 31, 2012:462–74adjustment for patient age, sex, race, diabetes, and hospital
status, both imaging results and the modality used were closely
associated with referral for early catheterization (Wald chi-
square test: 378.9, p  0.0001) (Table 2). The effect of PET
use was less than that of CCTA, but both were associated with
increased referral for catheterization. A significant interaction
between the modality used and study result was present such
that referral for catheterization rates differed betweenMPI and
CCTA in the setting of normal/nonobstructive and mildly
abnormal test results but not in the setting of moderately to
severely abnormal results (Fig. 2B).
The type of center where the study was performed or the
occurrence of another imaging study before the index study
was not associated with an increased referral for catheterization
rate. In a separate model, the use of SPECT, CCTA,
echocardiography, or exercise treadmill test in the 90 days
preceding the index study was not associated with increased
referral for catheterization. Finally, catheterization rates were
greater in patients who were men, those with angina, and those
of the white race.
We also repeated this analysis in the subset of 1,493
patients who did not undergo noninvasive procedures
before their index SPARC imaging study. The results
were very similar to the results of the analysis in the
overall cohort. The global chi-square was reduced (from
379 to 324), whereas modality used, study result, and
the modality used–study result interaction were all sta-
tistically significant. The odds ratios for these covariates
Figure 1 Frequency of Testing Before Enrollment
Relative frequency of stress test and/or imaging studies performed within 90 days
Imaging Roles in Coronary Artery Disease) by imaging arm. Comparisons of previo
test. The p value indicates that the frequency of previous studies differed by index
diography; ETT  exercise treadmill test; PET  positron emission tomography; SPwere similar to those described earlier. Unlike this wanalysis of the overall cohort, the PET-SPECT differ-
ence in referral for catheterization was no longer signif-
icant (p  0.12).
CARDIAC CATHETERIZATION RESULTS AND REFERRAL FOR
REVASCULARIZATION. Overall, 62.6% of patients (n 
102) referred for catheterization had evidence of obstruc-
tive CAD. The frequency of obstructive CAD was 54.2%
(n  24), 67.2% (n  61), 61.5% (n  78) found on
PECT, PET, and CCTA, respectively (p  0.517). The
roportions of patients without obstructive disease at
atheterization and a positive imaging study results was
9.1%, 28.3%, and 16.9%, respectively in SPECT, PET,
nd CCTA (SPECT vs. PET: p  NS, SPECT vs.
CTA: p  0.049), and the proportions of patients with
bstructive disease at catheterization and negative imag-
ng study results were 0.0%, 3.3%, and 20.8%, respec-
ively (SPECT vs. PET: p  NS, SPECT vs. CCTA:
 0.006).
In the setting of an imaging study with moderately to
everely abnormal findings, multivessel CAD was found
n 49%, 27%, and 30% of PET, CTA, and SPECT
atients, respectively. After an imaging study showing
ildly abnormal findings, multivessel CAD was found in
2%, 24%, and 0% of patients after PET, CCTA, and
PECT, respectively. Due to small numbers, these dif-
erences did not reach statistical significance.
Overall, there were 96 revascularization procedures
e enrollment in the SPARC (Study of Myocardial Perfusion and Coronary Anatomy
dies by modality are performed using the Cochran-Mantel-Haenszel chi-square
modality. CCTA  coronary computed tomography angiography; Echo  echocar-
single-photon emission computed tomography.befor
us stu
study
ECT ithin 90 days of the index study (Fig. 3). When
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January 31, 2012:462–74 Patient Management After Cardiac Imagingexpressed as a function of the overall cohort, the revas-
cularization rate after an imaging study with normal
findings was uniformly low across all modalities. Com-
pared with SPECT and PET, revascularization rates
were greater after CCTA, with the greatest differences in
the setting of a mildly abnormal study result (3.1%, 4.6%,
and 30.7%, respectively; p  0.001), but more similar
after studies with moderately to severely abnormal find-
ings (28.6%, 35.1%, and 44.1%, respectively; p  0.43).
mong patients referred for cardiac catheterization, the
requency of revascularization tended to be higher in
CTA patients than in MPI patients.
aseline and 90-day medication use. Baseline and 90-
ay medication use are summarized in Table 3. The
requency pattern of medication use was similar across all
Figure 2 Post-Test Referral for Cardiac Catheterization
(A) Relative frequency of referral for cardiac catheterization within 90 days after S
across study results and modalities were significant (Cochran-Mantel-Haenszel chi
rates between modalities within study result categories are indicated by asterisks
mildly abnormal are significant after Bonferroni adjustment for 3 multiple comparis
SPECT, PET, and CTA as a function of study result. Risk adjustment based on th
(Table 4). Adjustment includes consideration of patients’ age, sex, race, angin
shown represent contrasts between modalities. Contrasts assumed mean valu
in catheterization rates between modalities in normal/nonobstructive and mild
Abbreviations as in Figure 1.maging arms, with the exception of the lipid-loweringagent use, which was slightly higher in patients referred
for PET and CCTA (52.6% and 50.0%, respectively).
Comparing baseline with 90-day medication use in the
overall cohort, there were modest increases in the use of
all 3 medications. Overall, a significant association was
present between the number of medications used at the
time of the study and the degree of abnormality found on
the study (Cochran-Mantel-Haenszel chi-square test,
p  0.0049). In addition, there was an association
between the degree of abnormality found on the study
and the baseline use of aspirin and lipid-lowering agents
(both p  0.01), but not beta-blockers (p  0.0987).
MEDICATIONCHANGES,MODALITYUSED,ANDSTUDYRESULTS.
The frequency of use of each of the 3 medications increased
PET, and CCTA as a function of study result. Differences in catheterization rates
e test: p  0.001). Results of statistical testing of differences in catheterization
rences in catheterization rates among modalities in normal/nonobstructive and
B) Risk-adjusted rate of referral for cardiac catheterization within 90 days after
lts of general linear modeling using regions and sites as random effects
ptoms, diabetes, hospital status, and previous imaging study. The p values
numeric predictors and modality values of categorical predictors. Differences
ormal are significant after Bonferroni adjustment for 3 multiple comparisons.PECT,
-squar
. Diffe
ons. (
e resu
al sym
es of
ly abnfrom baseline to 90 days in almost all imaging modality
hospita
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Patient Management After Cardiac Imaging January 31, 2012:462–74subgroups. The absolute frequency in the use of aspirin,
beta-blocker, and lipid-lowering agent increased as a func-
tion of study results in the overall cohort both at baseline
Results of Multivariable Modeling of Referral forTable 2 Results of Multivariable Modeling o
Variable
W
Imaging modality (overall)
CCTA*
PET*
Imaging results (overall)
Mildly abnormal†
Moderately to severely abnormal†
Imaging modality  imaging results
PET: mild abnormality‡
CCTA: mild abnormality‡
PET: moderate to severe abnormality‡
CCTA: moderate to severe abnormality‡
Age group (overall), yrs
40–49§
50–59§
60–69§
70–79§
80§
Male
White race
Angina
Diabetes
Hospital status¶
Previous imaging study
*The odds ratios are for imaging modality (CCTA, PET) compared wi
imaging results (mild abnormality, moderate to severe abnormality) c
modality-study result pairing compared with normal findings on single-
compared with the patient age group younger than 40 years. The odd
¶The odds ratios are for studies done in an imaging center located in
CI  confidence interval; other abbreviations as in Table 1.
Figure 3 Post-Test Referral for Revascularization
Relative frequency of referral for coronary artery bypass graft (CABG) and percutan
abnormal cardiac imaging study results in patients referred for cardiac catheteriza
abnormal versus normal or nonobstructive CTA results (Cochran-Mantel-Haenszel,and at 90 days. A similar trend was also observed in almost
all imaging modality subgroups. In the overall cohort, there
was an association between the study result and the 90-day
iac Catheterization at 90 Dayserral for Cardiac Catheterization at 90 Days
i-Square Statistic
(p Value)
Adjusted Odds Ratio
(95% CI)
.4 (0.0001)
.4 (0.0001) 14.92 (3.52–63.27)
.0 (0.045) 5.03 (1.04–24.43)
.5 (0.0001)
.0 (0.0001) 28.45 (6.06–133.62)
.5 (0.0001) 199.23 (38.98–1,018.21)
.4 (0.015)
.5 (0.11) 0.24 (0.04–1.42)
.9 (0.34) 0.44 (0.08–38)
.1 (0.14) 0.25 (0.04–1.59)
.9 (0.009) 0.08 (0.01–0.53)
.4 (0.02
.7 (0.24) 4.13 (0.49–34.50)
.8 (0.11) 5.88 (0.73–47.23
.4 (0.09) 7.03 (0.87–56.51)
.5 (0.079) 7.39 (0.90–60.7)
.0 (0.25) 5.11 (0.54–48.39)
.2 (0.004) 1.82 (1.15–2.78)
.6 (0.003) 2.46 (1.35–4.50)
.1 (0.001) 3.11 (1.79–5.42)
.2 (0.68) 1.11 (0.69–1.78)
.1 (0.15) 1.52 (0.86–2.68)
0 (0.96) 0.99 (0.56–1.73)
le-photon emission computed tomography. †The odds ratios are for
d with a normal/nonobstructive study result. ‡The odds ratios are for
emission computed tomography. §The odds ratios are for age groups
are for the presence of this characteristic compared with its absence.
l compared with out of hospital.
oronary intervention (PCI) within 90 days after normal or nonobstructive versus
each of the 3 imaging arms. Revascularization rates were higher in patients with
.05). Abbreviations as in Figure 1.Cardf Ref
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beta-blockers (Table 3) (Cochran-Mantel-Haenszel chi-
square test, p  0.0002 and p  0.0001, respectively). A
similar association was also present within a number of
imaging modality subgroups (Table 3). Of note, among
patients with moderately to severely abnormal study results,
24% were not receiving aspirin, 44% were not receiving a
beta-blocker, and 23% were not receiving a lipid-lowering
agent at 90 days after the index study, and 40% were on
none of these medications or only taking 1 drug (Fig. 4). In
addition, 49% of these patients were not referred for
catheterization.
MULTIVARIABLE MODELING OF CHANGES IN MEDICAL
MANAGEMENT. Multivariable modeling using recruitment
site and the site’s geographic location as random effects
revealed that after adjustment for patient age, sex, race,
diabetes, hospital status, and the use of previous imaging
studies, the study result and, to a lesser degree, the use of
CCTA and the use of aspirin at baseline were most closely
associated with changes in the use of aspirin (change in
dose, addition or removal of the medication, change in class
of medication) (Table 4). Patient age and sex were also
associated with this endpoint. When this analysis was
limited to patients not taking aspirin at baseline, initiation
Aspirin, Beta-Blocker, and Lipid-Lowering Agent Frequency: BaselinTable 3 Aspirin, Beta-Blocker, and Lipid-Lowering Agent Freque
Aspirin, %
Baseline 90 Days
All patients
Overall 44.9 56.0*
Normal 43.2 52.7*
Mildly abnormal 45.8 60.8*
Moderate to severely abnormal 57.6† 76.3*†
p value 0.0002
SPECT
Overall 40.7 48.7
Normal 37.4 45.4
Mildly abnormal 49.0 56.3
Moderately to severely abnormal 64.3† 75.0†
p value 0.6958
PET
Overall 46.7 59.9*
Normal 47.5 56.3
Mildly abnormal 38.5 57.7*
Moderately to severely abnormal 57.1 79.2†
p value 0.0001
CCTA
Overall 47.1 59.5*
Normal 45.5 56.8*
Mildly abnormal 54.7 72.0
Moderately to severely abnormal 52.9 70.6
p value 0.0302
Values from a Cochran-Mantel-Haenszel chi-square test statistic of general association of the distrib
baseline frequency of medication use, overall and at each level of test result. †p  0.05 across ca
chi-square test of association with a Bonferroni adjustment of 0.01 for 5 comparisons.
Abbreviations as in Table 1.of aspirin after imaging was most closely associated with thestudy result and the modality used (Table 5). With respect
to this endpoint and patient subset, patients referred for
both PET and CCTA were more likely to be started on
aspirin compared with patients referred for SPECT.
Similar analysis of changes in the use of beta-blockers
(Table 4) revealed that only study results and patient age to
be associated with this endpoint; no such association was
present for the modality used. Examination of patients not
taking beta-blockers at baseline (Table 5) identified only
patient age to be associated with initiation of beta-blockers
and a borderline association with use of imaging before the
index study.
Finally, analysis of changes in lipid-lowering agent use
revealed the use of CCTA, study results, and patient age to
be most closely associated with changes in lipid-lowering
agent prescription (Table 4). With respect to patients not
taking lipid-lowering agents at baseline, lipid-lowering
agent initiation was most closely associated with these same
factors (Table 5).
Referral for cardiac catheterization and/or changes in
medication use after imaging. Overall, at 90 days after
imaging, neither referral for cardiac catheterization nor
medication changes occurred in 1,019 patients (59.8%),
both occurred in 104 patients (6.1%), referral for cardiac
d 90 DaysBaseline and 90 Days
Beta-blocker, % Lipid-Lowering Agent, %
Baseline 90 Days Baseline 90 Days
32.5 37.8* 48.9 58.7*
30.8 34.0 47.3 55.3*
35.2 44.9 49.2 64.5*
41.7 57.6† 62.6 77.0†
0.0001 0.2372
30.4 33.3 44.2 51.7
29.9 31.5 43.5 49.9
28.1 32.3 41.7 52.1
46.4 64.3† 64.3 78.6†
0.0001 0.1089
38.5 44.5 52.6 62.2*
38.4 41.3* 51.0 58.1
38.5 46.2 51.5 65.4
39.0 55.8 61.0 75.3†
0.0777 0.1370
28.8 35.9 50.0 62.2*
26.2 31.0 48.2 58.4*
38.7 58.7 54.7 78.7*
44.1 55.9† 64.7 79.4
0.0015 0.1361
f medication change as a function of test result and imaging modality. *p 0.05 for 90-day versus
of test results within time category (baseline and 90 days). These comparisons are based on thee anncy:
ution o
tegoriescatheterization without medication changes was observed in
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cardiac catheterization was documented in 521 (30.1%).
In the setting of normal or nonobstructive and mildly
abnormal study results, the frequency of patients neither
referred for catheterization nor having medication change
was the most frequent finding, with smaller numbers
Figure 4 Medical Therapy Before and After Noninvasive Testing
Absolute frequency of medication use at baseline and 90 days in the subgroup of
between frequencies of medication use are made using a chi-square test of assoc
LLA  lipid-lowering agent.
Modeling of Change in Medical Therapy With Adjustment for BaselTable 4 Modeling of Change in Medical Therapy With Adjustme
Variable
Predictors of 90-Day Change
in Aspirin
Wald Chi-Square
Statistic (p Value)
Adjusted Odds Ratio
(95% CI)
Wa
Stat
Imaging modality (overall) 8.1 (0.017)
CCTA 7.6 (0.006) 1.62 (1.15–2.29)
PET 0.5 (0.48) 1.14 (0.79–1.66)
Test result (overall) 16.7 (0.001)
Mildly abnormal 4.3 (0.038) 1.45 (1.02–2.05)
Moderate to severely
abnormal
12.4 (0.001) 2.24 (1.43–3.50)
Age group (overall), yrs 15.6 (0.008) 1
40–49 0.4 (0.51) 1.41 (0.51–3.90)
50–59 3.9 (0.047) 2.68 (1.01–7.12)
60–69 5.5 (0.019) 3.23 (1.21–8.58)
70–79 4.5 (0.033) 2.96 (1.09–8.06)
Male 8.9 (0.003) 1.52 (1.15–1.96)
White race 0.3 (0.60) 0.91 (0.65–1.29)
Angina 0.2 (0.64) 1.08 (0.77–1.52)
Diabetes 0.3 (0.61) 0.92 (0.67–1.27)
Hospital status 2.9 (0.087) 0.68 (0.44–1.06)
Previous imaging study 0.8 (0.38) 1.19 (0.81–1.75)
Use of medication at
baseline
16.5 (0.001) 0.57 (0.44–0.75)Abbreviations as in Tables 1 and 2.having a medication change without a referral for cardiac
catheterization, and few having both occur or only
referral for catheterization (both p  0.05) (Fig. 5). In
the setting of moderately to severely abnormal test
results, there were similar frequencies of patients in each
category (p  NS).
ts with moderately or severely abnormal imaging study results. Comparisons
. The p values indicate differences in baseline versus 90-day medication use.
edication User Baseline Medication Use
dictors of 90-Day Change
in Beta-Blockers
Predictors of 90-Day Change
in Lipid-Lowering Agents
Square
p Value)
Adjusted Odds Ratio
(95% CI)
Wald Chi-Square
Statistic (p Value)
Adjusted Odds Ratio
(95% CI)
.82) 22.3 (0.001)
0.96 (0.60–1.54) 22.3 (0.001) 2.2 (1.59–3.05)
0.86 (0.52–1.41) 0 (0.90) 1.02 (0.71–1.47)
.035) 30.4 (0.001)
.50) 0.89 (0.64–1.24) 11 (0.001) 1.75 (1.26–2.45)
.013) 1.82 (1.13–2.91) 19.4 (0.001) 2.63 (1.71–4.04)
.016) 30.9 (0.001)
.054) 0.42 (0.17–1.01) 4.1 (0.043) 3.57 (1.04–12.23)
.97) 1.01 (0.64–1.58) 9.1 (0.003) 6.39 (1.91–21.35)
.014) 1.69 (1.11–2.57) 8.6 (0.003) 6.12 (1.83–20.54)
.073) 0.69 (0.46–1.04) 7.3 (0.007) 5.41 (1.59–18.47)
.20) 2.62 (0.61–1.42) 2.4 (0.12) 0.82 (0.64–1.06)
.13) 3.14 (0.72–13.69) 1.0 (0.31) 1.19 (0.85–1.68)
.12) 3.26 (0.73–14.49) 3.6 (0.057) 1.37 (0.99–1.90)
.21) 0.61 (0.29–1.32) 0 (0.98) 1.00 (0.73–1.35)
.33) 2.24 (0.44–11.55) 0.3 (0.61) 0.89 (0.56–1.41)
.33) 1.23 (0.81–1.86) 0.3 (0.61) 0.91 (0.62–1.32)
.76) 1.09 (0.63–1.89) 0.4 (0.53) 1.08 (0.84–1.40)patien
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January 31, 2012:462–74 Patient Management After Cardiac ImagingBecause assessing changes in medication use can under-
estimate the thoroughness of medical therapy if multiple
medications are initiated before imaging, we examined the
number of medications used before imaging studies by
patients in the subgroup with moderately to severely abnor-
Results of Multivariable Modeling of Change in Medical Therapy inTable 5 Results of Multivariable Modeling of Change in Medica
Variable
Predictors of 90-Day Change
in Aspirin
Wald Chi-Square
Statistic (p Value)
Adjusted Odds Ratio
(95% CI)
Wa
Stat
Imaging modality (overall) 17.9 (0.001) 1
CCTA 11.1 (0.001) 2.14 (1.37–3.34)
PET 6.8 (0.009) 1.87 (1.17–2.98)
Test result (overall) 19.3 (0.001) 2
Mildly abnormal 4.1 (0.044) 1.59 (1.01–2.49)
Moderately to severely
abnormal
15.2 (0.001) 3.41 (1.84–6.32)
Age group (overall), yrs 10.3 (0.067)
40–49 1.63 (0.52–5.11) 1
50–59 2.38 (0.79–7.18) 3
60–69 3.44 (1.13–10.44) 11
70–79 2.48 (0.79–7.83) 0
80 1.17 (0.28–4.83) 0
Male 4.9 (0.027) 1.47 (1.04–2.08) 1
White race 0 (0.93) 0.98 (0.63–1.51) 1
Angina 3.0 (0.083) 1.50 (0.95–2.38) 2
Diabetes 0.4 (0.53) 1.15 (0.75–1.75) 1
Hospital status 3.8 (0.05) 0.59 (0.35–1.00) 0
Previous imaging study 0.6 (0.43) 1.23 (0.74–2.05) 3
N for predictors of aspirin use was 939, for changes in beta-blocker, 1,150, and for changes in lip
Abbreviations as in Tables 1 and 2.
Figure 5 Post-Test Changes in Patient Management
Frequency of referral for catheterization (Cath), medication (Med) change, both, or
Comparisons made with chi-square tests of association within each test result.mal study results who had no changes in medication at 90
days. In total, 24% of these patients were taking all 3 of the
medications (aspirin, beta-blocker, lipid-lowering agent)
and 32% were taking 2 of these medications. Interestingly,
16% of these patients were taking none of the medications,
nts Not Taking Medication at Baselinerapy in Patients Not Taking Medication at Baseline
dictors of 90-Day Change
in Beta-Blockers
Predictors of 90-Day Change
in Lipid-Lowering Agents
Square
p Value)
Adjusted Odds Ratio
(95% CI)
Wald Chi-Square
Statistic (p Value)
Adjusted Odds Ratio
(95% CI)
9) 15.2 (0.001)
1.01 (0.55–1.85) 13.8 (0.001) 2.42 (1.52–3.85)
0.62 (0.31–1.23) 1.4 (0.24) 1.35 (0.82–2.25)
9) 25.9 (0.001)
0.93 (0.58–1.49) 14.3 (0.001) 2.41 (1.53–3.79)
1.78 (0.86–3.68) 11.6 (0.001) 3.24 (1.65–6.38)
04) 16.6 (0.005)
7) 0.55 (0.19–1.60) 1.6 (0.20) 2.69 (0.59–12.3)
82) 1.88 (0.92–3.85) 4.7 (0.03) 5.16 (1.17–22.63)
.001) 3.1 (1.62–5.91) 4.2 (0.041) 4.74 (1.06–21.13)
7) 0.84 (0.47–1.53) 3.9 (0.05) 4.58 (1.00–20.89)
9) 2.49 (0.31–20.07) 2.2 (0.14) 3.57 (0.65–19.49)
1) 2.9 (0.37–22.40) 0.9 (0.35) 0.84 (0.59–1.21)
3) 3.5 (0.45–27.04) 0.6 (0.44) 1.21 (0.75–1.94)
6) 4.43 (0.56–35.33) 0.6 (0.42) 1.23 (0.74–2.03)
8) 0.54 (0.22–1.34) 1.2 (0.28) 1.29 (0.81–2.04)
7) 2.37 (0.23–24.89) 0.0 (0.89) 1.04 (0.60–1.81)
78) 1.77 (0.94–3.35) 0.0 (0.98) 0.99 (0.59–1.66)
ring agents, 870.
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than 2 medications. These rates did not differ from those in
the overall group of patients with moderately to severely
abnormal study results (Fig. 4).
Discussion
In the current study, we examined patient management after
noninvasive cardiovascular imaging, as measured by cathe-
terization referral and medical therapy changes at 90 days
after testing, in a prospective, multicenter registry of pa-
tients without previous CAD with a balanced representation
of nonacademic and academic practice settings. There are
several important findings. Overall, we found that cardio-
vascular imaging results had only a modest impact on
clinical management. Although the frequency of post-
imaging referral for catheterization and changes in medical
therapy increased in proportion to the degree of abnormality
found on imaging, we found that quantitatively the intensity
of change in patient management was relatively limited,
especially after moderately to severely abnormal test results.
In the latter group, the frequency of referral for catheter-
ization was only 62% after CCTA and 50% after MPI.
Likewise, cardioprotective medication use among patients
with the most abnormal study results was not uniformly
high; 24% were not taking aspirin, 23% were not taking a
lipid-lowering agent, and 43% were not taking a beta-
blocker. Moreover, a medication change occurred only in
approximately half of these patients, and both a referral for
catheterization and a change in medical therapy were
observed in only one-fourth of patients.
Second, we observed intermodality differences in cathe-
terization referral rates, with a greater observed referral
frequency after CCTA than after MPI (SPECT or PET) in
the setting of normal/nonobstructive and mildly abnormal
study results. Angiographically determined obstructive
CAD rates was highest after abnormal CCTA findings
(82%) and lower after abnormal findings on PET (74%) or
SPECT (59%), although the differences were not statisti-
cally significant.
Comparison with previous studies. Several previous ret-
rospective studies examined post-test catheterization refer-
ral, reporting unadjusted catheterization rates ranging be-
tween 40% and 70% in patients with significant ischemia,
with higher rates in patients with anginal symptoms, more
extensive ischemia, and higher clinical risk (5,10–15). To
date, limited data exist regarding changes in medication use
after routine imaging, although a randomized trial in a
lower risk cohort showed similar rates of medical manage-
ment (16). However, we are not aware of other comparisons
among cardiovascular imaging modalities with respect to
post-test patient management with regard to either
endpoint.
In the National Cardiovascular Data Registry, the yield
(defined as obstructive CAD prevalence in patients with
abnormal noninvasive study findings) of elective catheter-ization in patients without previous CAD was low (37.6%)
and showed a modest increase after a “positive”’ stress test
result (17). The current results differ from those of this
previous report, including differences in cohort composition
(National Cardiovascular Data Registry is an invasive reg-
istry; SPARC is a registry of noninvasive testing) and in the
manner in which data were recorded and submitted. The
National Cardiovascular Data Registry is a very large
national registry with many sites submitting various types of
data, but with relatively crude imaging results. SPARC, a
far smaller registry, includes detailed imaging data based on
careful, uniform interpretative and reporting criteria.
Clinical implications. In light of the enormous costs
associated with cardiovascular imaging, efforts have been
made to improve the appropriate use of medical imaging
(2–5). Many justify the use of these tests on grounds that
they play a central role in patient management and, al-
though an unproven hypothesis, improve patient outcomes.
The assumed paradigm is that in the setting of abnormal
study results—particularly high-risk results—patients un-
dergo intervention. The relatively limited changes in man-
agement after abnormal study results, especially high-risk
findings, undermine this paradigm, especially because in our
diagnostic cohort, these abnormalities represented a de novo
CAD diagnosis. Although the observed catheterization
rates can be explained by the perception of equipoise on the
part of referring physicians, it is more difficult to understand
or explain the patterns of medication use, especially among
patients with high-risk study results. In light of the costs
associated with cardiovascular imaging (4), it is problematic
to justify the use of testing that will not be incorporated into
subsequent patient care. A noninvasive procedure, the
results of which have no impact on subsequent manage-
ment, must be considered an inappropriate study; the
current study suggests that a significant amount of inappro-
priate noninvasive procedures are currently performed.
There are several possible explanations for these findings.
Physicians may have perceived equipoise between invasive
and conservative approaches, thus not referring many pa-
tients for catheterization. However, this would not explain
the frequency of medication use. Studies may have been
ordered for confirmatory purposes, validating physicians’
previous assessments, and optimal medical management was
initiated before imaging. This is consistent with the asso-
ciation between study results and the frequency of pre-study
medication use. Nonetheless, the fact that approximately
one-third of patients with high-risk study results were not
taking key medications after imaging suggests that a com-
ponent of patient undertreatment is present as well. One
cannot exclude the possibility that in a proportion of cases,
physicians ordered the tests “defensively,” feeling obligated
to document a response to a patient’s symptoms. However,
it would seem that action on study results would be more
likely justified in this scenario. Also, financial incentives on
the part of physicians ordering studies cannot be excluded.
Finally, it is possible that patients declined to undergo
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The former, however, was not reported in any interview. It
is also possible that at the time of follow-up, the patients
failed to fully inform the interviewer.
POST-IMAGINGPATIENTMANAGEMENTASAQUALITYMETRIC.
Quality of care has become a central issue in health care.
Recently, patient selection, image acquisition, image inter-
pretation, and results communication have been identified
as important components of imaging quality (18). However,
a well-performed imaging study in a high-quality laboratory
reported to the ordering physician is not a quality study if it
does not alter patient management, especially when the
study results constitute new findings or diagnoses. Hence,
referring physicians, implicated in this process via patient
selection, must also come under scrutiny to determine their
actions after notification of the study results. Although
impact on clinical management is a stated quality goal,
clinical outcomes were not considered feasible as a quality
measure (18). Results communication per se does not
necessarily ensure optimal patient care (19). The results of
the current study suggest that patient management after
noninvasive cardiac imaging should be considered a neces-
sary component of the definition of imaging quality.
Understanding intermodality differences. We found an
increased catheterization referral rate after CCTA com-
pared with PET and SPECT after mildly abnormal study
results, a category generally not associated with high clinical
risk or potential benefit with revascularization (5,20–22).
Nonetheless, the appropriateness of the referral for cathe-
terization pattern after abnormal imaging study results is
unclear. Whether this represents a relative catheterization
overuse or underuse will require prospective, randomized
clinical trial data.
The observed intermodality differences may be due to
differences in physician comfort and experience with these
modalities. Lower post-MPI catheterization rates may be
due to greater physician experience with post-MPI patient
management, understanding of post-test risk, and available
observational data on the lack of revascularization benefit in
patients with mild ischemia. Conversely, greater post-
CCTA catheterization and revascularization rates may be
due to the greater sensitivity of the test, the occulostenotic
reflex, overestimation of stenoses on CCTA, and less
familiarity with managing patients on the basis of CCTA
results.
Study strengths and limitations. The most important
limitation of the current study is the issue of whether the
findings in our current cohort are unique or generalizable to
outside populations. Unfortunately, we were not able to
collect extensive data on patients presenting for testing at
our recruitment sites who were not enrolled in the SPARC,
information that would have informed us regarding the
SPARC cohort’s generalizability. Thus, we cannot say with
certainty whether the SPARC cohort and the findings
reported in the current paper are unique or characteristic ofwidespread practice. Nonetheless, previous single-site stud-
ies report catheterization referral rates similar to those that
we observed in the SPARC (5,10–13).
Although randomized clinical trials enhance the validity
of comparisons among imaging modalities, a prospective
registry design enhanced our ability to observe patterns of
care in daily clinical practice. Similarly, we used sites’ clinical
interpretations of imaging studies rather than those of core
laboratories. Other than the collection of semiquantitative
scoring data, all recruiting centers adhered to their routine
practice with respect to all aspects of testing and reporting.
Although cardiac SPECT is an established imaging
modality, PET and CCTA are relatively newer modalities
and physicians’ use patterns may not yet be established.
With more experience, catheterization and medical therapy
use after testing may change. Issues of heterogeneity in
payer policies for these 3 modalities may further obfuscate
comparisons of post-test management. Nonetheless, these
issues should have less of an impact on post-test referral for
catheterization or changes in medication use than on the
composition of who is referred for imaging. It is possible
that the results of the index study may have resulted in
referral for additional noninvasive studies. It was a limita-
tion of the study design that this information was not
collected. However, we did collect data on pre-index study
noninvasive procedures and used those data to examine the
role and impact of sequential testing.
The characteristics of the patients enrolled in each of the
3 arms differed, as did the frequency of abnormal study
results. Although every effort was made to adjust for these
potential differences using multivariable modeling, this ap-
proach is not without limitations including that of unmea-
sured covariates.
Conclusions
Overall, noninvasive studies had only a modest impact on
the clinical management of patients referred for clinical
testing. Although post-imaging use of cardiac catheteriza-
tion and medical therapy increase in proportion to the
degree of abnormal study results, the frequency of catheter-
ization and medication use suggest possible undertreatment
of higher-risk patients. Compared with stress MPI, cathe-
terization referral rates and subsequent need for revascular-
ization are greater after CCTA, but the rates of medication
use are similar.
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